Effect of Eurycoma longifolia water extract (Physta®) on menopausal quality of life and mood states

Table 2 Data of menopause-specific quality of life and profile of mood states of Physta^® 50 mg, 100 mg, and placebo at baseline, week 6 and week 12

Parameter	Placebo (n = 40)			Physta® 50 mg (n = 36)			Physta® 100 mg (n = 36)
	Baseline	Week 6	Week 12	Baseline	Week 6	Week 12	Baseline	Week 6	Week 12
MENQOL
Vasomotor	3.12 ± 1.80	2.59 ± 1.60b	2.41 ± 1.27c	3.35 ± 2.12	2.43 ± 1.32b	2.51 ± 1.49	3.68 ± 2.09	2.94 ± 1.74b	2.45 ± 1.67d
Psychosocial	3.12 ± 1.36	2.49 ± 1.33b	2.61 ± 1.22d	3.00 ± 1.48	2.53 ± 1.34b	2.51 ± 1.43d	3.62 ± 1.60	2.75 ± 1.22b	2.65 ± 1.47d
Physical	3.98 ± 1.27	2.91 ± 1.22b	2.93 ± 1.48d	3.94 ± 1.18	2.96 ± 1.14b	2.85 ± 1.37d	4.45 ± 1.15	2.99 ± 1.12b	2.83 ± 1.33d,f
Sexual	3.38 ± 1.94	2.58 ± 1.44b	2.69 ± 1.46c	3.53 ± 1.76	2.81 ± 1.34a	2.65 ± 1.46d	3.94 ± 1.86	2.69 ± 1.51b	2.51 ± 1.46d,f
Total MENQOL	104.95 ± 35.48	79.53 ± 33.43b	80.45 ± 37.27d	104.67 ± 33.39	80.72 ± 31.25b	78.58 ± 38.15d	119.11 ± 35.52	83.92 ± 32.42b	78.75 ± 37.64d,f
POMS
Tension	9.03 ± 4.81	8.10 ± 5.10	8.33 ± 4.69	10.14 ± 5.69	9.44 ± 5.02	9.03 ± 5.17	10.89 ± 6.34	9.92 ± 6.61	8.53 ± 5.19c
Depression	9.05 ± 8.16	7.85 ± 10.47	8.03 ± 9.37	10.28 ± 11.55	10.97 ± 10.96	9.72 ± 9.60	13.17 ± 12.98	11.39 ± 12.08	8.97 ± 9.60d
Anger	9.45 ± 6.98	8.08 ± 8.49	8.25 ± 6.92	10.36 ± 8.33	10.36 ± 8.28	9.33 ± 8.11	12.50 ± 9.14	10.83 ± 10.00	10.78 ± 11.85
Vigor	17.70 ± 3.98	18.25 ± 4.87	19.20 ± 4.86	19.00 ± 5.74	18.83 ± 6.10	19.22 ± 5.35	17.06 ± 5.24	18.38 ± 4.96	18.03 ± 4.97
Fatigue	8.73 ± 4.97	6.30 ± 5.45b	6.20 ± 5.36d	9.14 ± 5.91	7.58 ± 5.28	6.25 ± 5.14c	11.36 ± 6.07	7.50 ± 5.80b	7.17 ± 8.17d
Confusion	7.97 ± 4.18	6.55 ± 4.15a	6.95 ± 3.86	7.36 ± 4.28	7.50 ± 4.14	6.64 ± 3.87	8.42 ± 4.80	7.36 ± 5.03	6.69 ± 4.28c
Total mood disturbance	26.53 ± 27.30	18.63 ± 31.63	18.55 ± 28.88	28.28 ± 34.66	27.03 ± 31.50	21.75 ± 30.06	39.28 ± 37.61	28.72 ± 37.12a	24.11 ± 35.48d

^aP < 0.05 from baseline to week 6.

^bP < 0.01 from baseline to week 6.

^cP < 0.05 from baseline to week 12.

^dP < 0.01 from baseline to week 12.

^fP < 0.05 for Physta^® 100 mg vs placebo.

Data are presented as mean ± SD scores for menopause-specific quality of life and profile of mood states parameters across placebo, Physta^® 50 mg, and Physta^® 100 mg groups at baseline, week 6, and week 12. Mixed analysis of variance was used to assess time-by-group interaction effects, and paired and independent t-tests were used for within-group and between-group comparisons, respectively. MENQOL: Menopause-specific quality of life; POMS: Profile of mood states.